News

The objective of this trial is to assess escalating single doses of REN-850 in approximately 45 healthy volunteers. This trial will represent the first step towards establishing the

Reducing the frequency of seizures remains a significant challenge in treating patients with epilepsy. In fact, more than one-third of epilepsy patients continue to experience seizures while taking

In a colorectal cancer model, the inclusion of CA4P in a two-week treatment regime with Avastin extended the time to progression of these tumors to five times treatment

The study data was obtained by applying Ambit’s novel kinase profiling technology to evaluate the specificity of 20 compounds and reveal potential new uses for some. “Kinases play

TheraQuest believes its unique formulation, TQ-1017, slated for phase III clinical trials in 2005, may have significant safety advantages over other formulations currently in development. Tramadol’s pain relieving

The drug is an antisense inhibitor of thymidylate synthase (TS), a well-known drug target that protects cancer cells from the effects of several chemotherapy treatments. In preclinical studies,

KOS-862 (Epothilone D) is a polyketide that inhibits cancer cells by the same mechanism as paclitaxel (marketed as Taxol by Bristol-Myers squibb). Preclinical models have shown the compound

The trial, named STRIDE-2, met its primary endpoint of improved six minute walk (6MW) distance in patients receiving a 100mg dose of Thelin (sitaxsentan), with a placebo-subtracted improvement

The study, published in a peer-reviewed American Cancer Society journal, found that the benefit becomes pronounced within two years of therapy and is maintained throughout its use. Tamoxifen